The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
about
Developments in FTICR-MS and Its Potential for Body Fluid SignaturesMass spectrometry-based proteomics for pre-eclampsia and preterm birthSerum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assaysProteomics and mass spectrometry for cancer biomarker discoveryAutomated assignment of ionization states in broad-mass matrix-assisted laser desorption/ionization spectra of protein mixtures.Informed baseline subtraction of proteomic mass spectrometry data aided by a novel sliding window algorithm.Studying multiple protein profiles over time to assess biomarker validity.Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum.LIMPIC: a computational method for the separation of protein MALDI-TOF-MS signals from noise.Serum albumin-associated peptides of patients with uterine endometrial cancer.Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum.Independent component analysis for the extraction of reliable protein signal profiles from MALDI-TOF mass spectra.A new strategy for faster urinary biomarkers identification by Nano-LC-MALDI-TOF/TOF mass spectrometry.Approaching clinical proteomics: current state and future fields of application in fluid proteomics.Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry.A novel strategy for proteome-wide ligand screening using cross-linked phage matricesA gel-free approach in vascular smooth muscle cell proteome: perspectives for a better insight into activationPotential biomarkers for esophageal carcinoma detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.Discrimination of different species from the genus Drosophila by intact protein profiling using matrix-assisted laser desorption ionization mass spectrometry.A Bayesian network approach to feature selection in mass spectrometry dataHigh-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery.Modeling the time evolution of the nanoparticle-protein corona in a body fluid.Searching for Potential Ovarian Cancer Biomarkers with Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.Proteomic profiling of uremia in serum using magnetic bead-based sample fractionation and MALDI-TOF MS.Enhancement in MALDI-TOF MS analysis of the low molecular weight human serum proteomeIdentification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis.Strategy for degradomic-peptidomic analysis of human blood plasmaDetection of cancer cells in the cerebrospinal fluid: current methods and future directions.Some views on proteomics in diabetes.Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.Proteomics and mass spectrometry: what have we learned about the heart?Improved signal processing and normalization for biomarker protein detection in broad-mass-range TOF mass spectra from clinical samples.Robust substrate profiling method reveals striking differences in specificities of serum and lung fluid proteases.Selective enrichment and sensitive detection of peptide and protein biomarkers in human serum using polymeric reverse micelles and MALDI-MSFunctional protease profiling for diagnosis of malignant disease.The Use of Principal Component Analysis in MALDI-TOF MS: a Powerful Tool for Establishing a Mini-optimized Proteomic ProfileMass spectrometry for the molecular imaging of angiotensin metabolism in kidney.Proteomic profiling of nephrotic syndrome in serum using magnetic bead based sample fractionation & MALDI-TOF MS.Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia.Serum proteomic, peptidomic and metabolomic profiles in myasthenia gravis patients during treatment with Qiangji Jianli Fang.
P2860
Q26863208-91B7C4BE-4A8A-4C83-83CA-18C4A5157297Q28083761-358DA788-72A3-43EB-9FBE-20C8A016D35AQ28743469-6C2A2103-D716-4FCD-8639-8110ABF7D652Q28766969-DD476E84-D64E-45F1-887A-88A78B8564F6Q30953230-B33FD01E-2197-401D-94B3-D94C9CB2E5ACQ31149213-3FB7D5B2-A36D-4D79-B8B0-AE9D50FCF942Q33253535-5F6A1DDA-85AA-46DB-AB89-C447BCBBC2DEQ33259972-DC0A03FF-5FE7-4329-8F16-7EBF5EF02879Q33280025-12C3526F-B97D-47E2-AF94-16B00B358AA4Q33281557-984E4E3E-7922-4F76-B4A3-1784380DF8B0Q33295308-24699B4B-6160-4408-8E74-04BC70B2B232Q33305606-33217669-2383-4D03-A1FE-C00CAB5B0947Q33384944-1F578384-FB53-4CBF-A845-13305E9D307AQ33467523-A6359373-3095-49B0-A08A-94F3D889F77BQ33514542-1C1082CB-15C9-47EF-BDCC-C6CF310A22ABQ33527745-85B54C12-2019-49C4-A601-021A213541ABQ33545430-B0A57720-9ECA-49C0-A7B7-E5001346522AQ33546553-084263B4-72DB-4652-99AA-DA75C7266F23Q33550572-4C8F2D6E-4F45-490F-8CE1-DBBED7C55633Q33551051-616F41ED-A94A-4209-90C3-C59A4A156576Q33579375-B7A5E0BD-C35C-410A-802D-AB8A84DBF411Q33598483-3221B394-3636-43E0-B64F-093E3B6408D7Q33642806-0D532447-2FA1-402D-91BF-9DE627A339E8Q33721224-27F6770D-533D-4D8A-8732-3F4671836C92Q33781592-4F081A27-2726-4BD9-A1FF-6C3546CC9653Q33813676-E968A578-0AFE-4590-8163-95E5DF0AA5C6Q33835867-C0EC3F21-BCA4-4F5D-B5A7-5121C970CE8FQ33836335-30FD0D92-F8EB-4B89-B5FA-A1694089291CQ33848339-01208FF5-EA63-46EF-B07C-097D7EB15124Q33921490-796A9CB5-3CA2-4E54-801F-DA6458ABD0F3Q33940880-53F9EABD-F3DD-44F6-A939-8C6795B477A2Q33959634-990546E7-687A-457D-8FB7-6008692AE9A6Q33977518-4B13DED9-354A-489B-9620-1D1C3B1BE7E0Q34109421-6BC112EB-253E-4679-8421-308F4276EF4FQ34116114-FCF97A76-FBE9-4F88-8789-266F412AD189Q34121793-43D97E4D-C62E-4D51-8F64-F985DB789199Q34154249-28B4EAA0-5AC1-4950-9B14-0B33EDA534BCQ34259029-4B272E46-188E-45CC-B73D-655E0675CCD3Q34333169-A672235B-E61D-4EFD-9E6F-A4A5AD2427D2Q34354027-3B741649-5C9C-4276-8848-D6FE17E6FB40
P2860
The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
@ast
The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
@en
type
label
The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
@ast
The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
@en
prefLabel
The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
@ast
The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
@en
P1433
P1476
The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
@en
P2093
Glen L Hortin
P304
P356
10.1373/CLINCHEM.2006.069252
P407
P577
2006-04-27T00:00:00Z